1Richardson PG,Sonneveld P,Schuster M, et al. Extended follow- up of a phase 3 trial in relapsed multiple myeloma: final time-to- event results of the APEX trial[J]. Blood, 2007,110:3557-3560.
2Blade J,Perales M,Rosinol L,et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas [J]. Br J Haematol, 2001,13 : 422-425.
3Lonial S,Waller EK, Richardson PG, et al. Risk factors and kinetics of thromhocytopenia associated with bortezomih for relapsed, refractory multiple myeloma[J]. Blood, 2005,106 : 3777- 3784.
4Shah MH,Young D,Kindler HL,et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors[J]. Clin Cancer Res,2004, 10: 6111- 6118.
同被引文献5
1Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time- to-event analyses of the multicenter phase 2 PINNACLE study [J]. Ann Oncol,2009,20(3) :520-525.
2Ghosh N, Ye X, Ferquson A, et al. Bortezomib and thalido- mide. a steroid free regimen in newly diagnosed patients with multiple myeloma [ J ]. Br J Haematol, 2011,152 ( 17 ) : 593-598.
